Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents.

Détails

ID Serval
serval:BIB_0E84A0C0066A
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents.
Périodique
Antimicrobial Agents and Chemotherapy
Auteur(s)
Carmeli Y., Troillet N., Eliopoulos G.M., Samore M.H.
ISSN
0066-4804 (Print)
ISSN-L
0066-4804
Statut éditorial
Publié
Date de publication
1999
Peer-reviewed
Oui
Volume
43
Numéro
6
Pages
1379-1382
Langue
anglais
Notes
Publication types: Comparative Study ; Journal Article
Publication Status: ppublish
Résumé
Pseudomonas aeruginosa is a leading cause of nosocomial infections. The risk of emergence of antibiotic resistance may vary with different antibiotic treatments. To compare the risks of emergence of resistance associated with four antipseudomonal agents, ciprofloxacin, ceftazidime, imipenem, and piperacillin, we conducted a cohort study, assessing relative risks for emergence of resistant P. aeruginosa in patients treated with any of these drugs. A total of 271 patients (followed for 3,810 days) with infections due to P. aeruginosa were treated with the study agents. Resistance emerged in 28 patients (10.2%). Adjusted hazard ratios for the emergence of resistance were as follows: ceftazidime, 0.7 (P = 0.4); ciprofloxacin, 0.8 (P = 0.6); imipenem, 2.8 (P = 0.02); and piperacillin, 1.7 (P = 0.3). Hazard ratios for emergence of resistance to each individual agent associated with treatment with the same agent were as follows: ceftazidime, 0.8 (P = 0.7); ciprofloxacin, 9.2 (P = 0.04); imipenem, 44 (P = 0.001); and piperacillin, 5.2 (P = 0.01). We concluded that there were evident differences among antibiotics in the likelihood that their use would allow emergence of resistance in P. aeruginosa. Ceftazidime was associated with the lowest risk, and imipenem had the highest risk.
Mots-clé
Adult, Aged, Aminoglycosides, Anti-Bacterial Agents/pharmacology, Ciprofloxacin/pharmacology, Drug Resistance, Microbial, Female, Humans, Male, Middle Aged, Pseudomonas aeruginosa/drug effects, Risk
Pubmed
Création de la notice
28/12/2013 17:43
Dernière modification de la notice
20/08/2019 12:35
Données d'usage